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SObjective: The aim of this study was to assess the influence of lymphatic and vascular invasion on overall
survival in patients with surgically resected non–small cell lung cancer (NSCLC) without lymph node and dis-
tant metastases.
Methods: From January 1999 to December 2009, a total of 190 NSCLC patients with node-negative pT1-pT4
disease underwent radical resection with lymphadenectomy. Pathologic reports were reclassified to the TNM-7
version, and the influence of lymphatic and vascular invasion on overall survival was examined using
Kaplan-Meier and adjusted Cox proportional hazards analyses.
Results: Lymphatic invasion was present in 34 (17.9%) and vascular invasion in 28 (14.7%) of 190 cases. Lym-
phatic and vascular invasions were correlated with higher Union for International Cancer Control stages
(P ¼ .056 and P ¼ .011, respectively) and poor differentiated tumors (P ¼ .051 and P ¼ .012, respectively).
There was no difference between pT1a and pT1b tumors in the presence of lymphatic (P ¼ .912) or vascular
(P ¼ .134) invasion. Survival analyses revealed lymphatic (P< .001) and vascular (P ¼ .008) invasion as
statistically significant for the entire study population. Multivariable Cox analysis adjusted for age, Union for
International Cancer Control stage, and lymphatic and vascular invasion confirmed lymphatic, but not vascular,
invasion as an independent prognostic factor (P < .001; hazard ratio, 3.002; 95% confidence interval,
1.780-5.061). Especially in early stages, lymphatic invasion was associated with poorer overall survival in
pT1a (P<.001), pT1b (P ¼ .019), and pT2a (P ¼ .028) tumors.
Conclusions: Lymphatic invasion represents an independent risk factor for node-negative NSCLC. Its
implications on therapy decision making should be further evaluated, especially in early stages. (J Thorac
Cardiovasc Surg 2013;146:781-7)Even in the early stages of non–small cell lung cancer
(NSCLC), patients form a heterogeneous groupwith interin-
dividual differences in survival. To improve the staging, the
seventh edition of tumor, nodes, andmetastasis (TNM) clas-
sification for NSCLC was introduced in 2009.1 Yet,
nonanatomic cancer characteristics, such as tumor grading
and vascular and lymphatic invasion, have not been consid-
ered as influencing factors on stage classifications.2
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The Journal of Thoracic and Cain histopathologic specimen evaluation may add to improve
the assessment of a tumor risk profile and help to stratify pa-
tients in need of an adjuvant therapy. The group of patients
with stage IANSCLC is especially of interest, because adju-
vant therapy is generally not administrated in this setting.
In other solid malignancies, such as breast, colon, and
gastric cancer, lymphatic invasion has already been identi-
fied as a negative prognostic factor for survival.3-5 In
NSCLC, the influence of lymphatic and vascular invasion
on patient prognosis and its role in therapy planning are
still under debate.
Therefore, the aim of the present study was to evaluate
the role of lymphatic and vascular invasion as a potential
factor influencing patient survival in our study population,
especially in the early stages.METHODS
Patients
We retrospectively reviewed the records of 190 patients with NSCLC
(pT1-pT4 N0M0), with available information on lymphatic and vascular
invasion status, who underwent surgical resection at the Department of
General, Visceral and Thoracic Surgery, University Medical Center
Hamburg-Eppendorf (Hamburg, Germany) between January 1999 and
December 2009.rdiovascular Surgery c Volume 146, Number 4 781
Abbreviations and Acronyms
CT ¼ computed tomographic
NSCLC ¼ non–small cell lung cancer
TNM ¼ tumor, nodes, and metastasis
UICC ¼ Union for International Cancer Control
YSR ¼ year survival rate
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SPreoperative evaluation included patients’ medical history, physical ex-
amination, plain chest X-ray, thoracic computed tomographic (CT) scan,
bone scan, abdominal ultrasound, and fiberoptic bronchoscopy and posi-
tron emission tomography–CT, according to national guidelines.6 Media-
stinoscopy, brain magnetic resonance imaging, or CT scan was only
performed in selected cases.
Surgical procedures consisted of standard lobectomy, bilobectomy, and
pneumonectomy. All resections included a systematic dissection of hilar
and mediastinal lymph node stations, according to the Japan Lung Cancer
Society map.7 Data collection was done prospectively. Follow-up was done
on a regular outpatient setting via contacting the patient or the patient’s pri-
mary care physician and included data on deaths of any cause. The study
was approved by the Ethics Committee of the Chamber of Physicians in
Hamburg, and written informed consent was obtained from all patients par-
ticipating in this study.
Patients were excluded from this study if a synchronous or metachro-
nous (up to 1 year after first resection) second malignancy other than
NSCLC was present, in cases with tumor residual disease (R1 or R2) or
if a wedge resection without systematic lymphadenectomy was performed.
Patients with 30-day-mortality were also excluded to avoid blurring of sur-
vival estimation, as were patients with a follow-up shorter than 6 months
(Figure 1). The mean follow-up of the censored patients was 55.2 months
(range, 8.6-197.0 months).
The mean patient age was 65.1 years (range, 38.1-91.9 years). Surgical
procedures included 153 (80.0%) lobectomies, 12 (6.3%) bilobectomies,
11 atypical resections with lymphadenectomy (5.8%), and 14 (7.4%)
pneumonectomies. Lymphatic invasion was present in 34 (17.9%), and
vascular invasion was present in 28 (14.7%), of 190 cases.
Histopathologic Evaluation
Histopathologic studies included characteristics on tumor histology
(adenocarcinoma, squamous cell carcinoma, and large-cell carcinoma),
tumor location, tumor size, tumor grading, lymph node status, lymphatic
invasion, vascular invasion, and resection margin status. To assess the lym-
phatic and vascular invasion status, sections were stained routinely by the
Elastica van Gieson and the hematoxylin-eosin methods. Histopathologic
diagnosis of lymphangioinvasion was made by a board-certified patholo-
gist on clearly distinguishable clusters of tumor cells (4 tumor cells)
within spaces with endothelial lining in close relationship with venous ves-
sels. In all cases with unclear findings, additional immunohistochemical
staining using antibodies specific for endothelial cells (CD31 and D2-40;
Dako, Glostrup, Denmark) was performed. The evaluation also included
cytokeratin staining for verification of carcinoma cells within lymphatic
vessels. Exemplarily histopathologic sections are given in Figure 2. All
cases were classified or reclassified based on the seventh edition of the
TNM classification system.1
Statistical Analysis
Continuous data are given as median, including ranges. Categorical var-
iables are shown as numbers and percentages. Long-term survival was es-
timated using the nonparametric product limit method (Kaplan-Meier).
Multivariate Cox proportional hazards regression models were used for782 The Journal of Thoracic and Cardiovascular Surgexamination of competing risk factors (including parameters with univari-
ate P<.10) and given with corresponding hazard ratios and 95% confi-
dence intervals. Statistical significance was assumed at 2-tailed P<.05.
Statistical calculation was performed with the PASW 18.0 Software pack-
age (SPSS Inc, Chicago, Ill), and survival curves were plotted with the R
statistics software 2.15.2 (R Foundation for Statistical Computing, Vienna,
Austria).
RESULTS
Table 1 depicts the tumor-specific characteristics of the
entire study population, stratified according to the presence
of lymphatic and vascular invasion.
We showed a borderline significant correlation between
lymphatic (P ¼ .056) and a significant correlation between
vascular (P ¼ .008) invasion and Union for International
Cancer Control (UICC) stages. In addition, a parallel asso-
ciation between presence of lymphatic and vascular inva-
sion was evident (P< .001). Lymphatic (P ¼ .051) and
vascular (P ¼ .012) invasions were more often present in
poorer differentiated tumors. Interestingly, there was no dif-
ference between pT1a and pT1b tumors in the presence of
lymphatic (P ¼ .912) or vascular (P ¼ .134) invasion.
Impact of Lymphatic and Vascular Invasion on
Survival
Univariable analysis of the final study population re-
vealed lymphatic invasion (P< .001), vascular invasion
(P ¼ .008) (Figure 3, A and B), pT (P<.001), and UICC
stage (P < .001) as statistically significant prognostic
factors.
In multivariable Cox analysis, lymphatic invasion was
confirmed as an independent prognostic factor (P<.001;
hazard ratio, 3.002; 95% confidence interval, 1.780-
5.061) for overall survival. All results of the univariable
and multivariable analyses (including the parameters of
lymphatic and vascular invasions, UICC stage, and age)
are summarized in Table 2.
Applying the UICC staging system, the presence of lym-
phatic invasion negatively affected patient survival in stages
IA (P<.001) and IB (P ¼ .028), but not in higher stages.
The 5-year survival rate (YSR) in stage IA patients was lim-
ited to 15%with the presence of lymphatic invasion in con-
trast to 68%without it. In stage IB, the 5-YSR was 52% for
patients without lymphatic invasion versus 31% for patients
with lymphatic invasion (Figure 3, C and D).
Because the UICC stage IA was composed of 43 pT1a
and 39 pT1b tumors, the influence of lymphatic invasion
was assessed for each of the subgroups separately. Interest-
ingly, lymphatic invasion was associated with poorer over-
all survival in pT1a (P<.001) and pT1b (P¼ .019) tumors.
In addition, pT2a (P¼ .028) tumors with positive lymphatic
invasion had a poorer outcome, but not pT2b (P ¼ .085),
pT3 (P ¼ .923), and pT4 (P ¼ .157) tumors.
The 5-YSR in pT1a patients was 14% with presence of
lymphatic invasion compared with 75% without presenceery c October 2013
FIGURE 1. Flow diagram demonstrating the exclusion of patients. L,
Lymphatic; V, vascular; NSCLC, non–small cell lung cancer; BAC,
bronchioloalveolar carcinoma.
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a similar survival trend was observed because the 5-YSR
decreased to 16% if histologically the presence of
lymphatic invasion was confirmed, whereas it was 61%
without tumor cells penetrating lymphatic vessels
(P ¼ .019).
Regarding vascular invasion, the 5-YSR in stage IA was
30% for patients with vascular invasion and 61% for
patients without vascular invasion, without statistical
significance (P ¼ .107) and possibly because of the few
Vþ patients.DISCUSSION
As our data show, the presence of lymphatic and vascular
invasion is associated with a poorer patient outcome in
early-stage NSCLC. Lymphatic invasion was identified as
an independent risk factor in stage IA tumors. Interestingly,
the negative effect of lymphatic and vascular invasion
vanished in higher disease stages.FIGURE 2. Representative tissue sections of non–small cell lung cancer tumor
methods (A and B) and with the monoclonal antibody D2-40 (C and D).
The Journal of Thoracic and CaThe process of metastasis formation is based on the abil-
ity of tumor cells to loosen from their primary tumor cell
mass and invade to lymphatic and/or vascular structures.
Therefore, the presence of angioinvasion demonstrates
a state of already advanced and more aggressive tumor
behavior.8 Because selected patients have a significantly re-
duced survival, although being treated at the same early
stage of disease, additional factors not considered in the
TNM classification influence the course of disease.9
Several studies report on a potential influence of lym-
phatic and vascular invasion on survival.10-12 These
studies show a high discordance in design, volume,
results, and conclusions. Early studies from Shields11 and
Brechot and colleagues10 demonstrated a correlation be-
tween positive lymphatic invasion and poor prognosis for
patients with NSCLC. However, Shields11 reported on no
prognostic value for vascular invasion. In contrast, Gold-
stein and colleagues12 proposed lymphatic invasion as
a prognostic factor for recurrence in their series of 218 stage
I NSCLC cases. Performing separate analyses of lymphatic
and vascular invasion and focusing on early disease stage,
as done herein, 2 studies have reported on similar
results.13,14 Hanagiri and colleagues13 showed, in 226 re-
sected stage I NSCLC patients, a significantly poorer out-
come for patients with positive lymphatic or positive
vascular invasion. In a similar study with 229 resected stage
I NSCLC patients, Funai and colleagues14 report on signif-
icantly worse survival of patients with lymphatic invasion
compared with patients without lymphatic invasion. Con-
trarily, a study by Gabor and colleagues15 identified onlys with the presence of lymphatic invasion stained by the hematoxylin-eosin
rdiovascular Surgery c Volume 146, Number 4 783
TABLE 1. Lymphatic and vascular invasion in correlation to clinicopathologic data (n ¼ 190)
Clinicopathologic features
Lymphatic invasion Vascular invasion
L0
156 (82.1)
L1
34 (17.9) P value
V0
162 (85.3)
V1
28 (14.7) P value
Age, y
<60 (n ¼ 55) 44 (80.0) 11 (20.0) 47 (85.5) 8 (14.5)
60-<70 (n ¼ 66) 52 (78.8) 14 (21.2) 54 (81.8) 12 (18.2)
70 (n ¼ 69) 60 (87.0) 9 (13.0) .414 61 (88.4) 8 (11.6) .558
Sex
Female (n ¼ 61) 55 (90.2) 6 (9.8) 56 (91.8) 5 (8.2)
Male (n ¼ 129) 101 (78.3) 28 (21.7) .046 106 (82.2) 23 (17.8) .080
Tumor
pT1a (n ¼ 43) 36 (83.7) 7 (16.3) 42 (97.7) 1 (2.3)
pT1b (n ¼ 39) 33 (84.6) 6 (15.4) 35 (89.7) 4 (10.3)
pT2a (n ¼ 63) 55 (87.3) 8 (12.7) 51 (81.0) 12 (19.0)
pT2b (n ¼ 21) 17 (81.0) 4 (19.0) 17 (81.0) 4 (19.0)
pT3 (n ¼ 21) 14 (66.7) 7 (33.3) 16 (76.2) 5 (23.8)
pT4 (n ¼ 3) 1 (33.3) 3 (66.7) .085 1 (33.3) 2 (66.7) .011
UICC stage
IA (n ¼ 82) 69 (84.1) 13 (15.9) 77 (93.9) 5 (6.1)
IB (n ¼ 63) 55 (87.3) 8 (12.7) 51 (81.0) 12 (19.0)
IIA (n ¼ 20) 16 (80.0) 4 (20.0) 16 (80.0) 4 (20.0)
IIB (n ¼ 22) 15 (68.2) 7 (31.8) 17 (77.3) 5 (22.7)
IIIA (n ¼ 3) 1 (33.3) 2 (66.7) .056 1 (33.3) 2 (66.7) .008
Histology
ACC (n ¼ 93) 78 (83.9) 15 (16.1) 83 (89.2) 10 (10.8)
SCC (n ¼ 74) 63 (85.1) 11 (14.9) 62 (83.8) 12 (16.2)
LCC (n ¼ 23) 15 (65.2) 8 (34.8) .077 17 (73.9) 6 (26.1) .160
WHO
G1 þ G2 (n ¼ 111) 96 (86.5) 15 (13.5) 101 (91.0) 10 (9.0)
G3 þ G4 (n ¼ 77) 58 (75.3) 19 (24.7) .051 60 (77.9) 17 (22.1) .012
Data are given as number (percentage). P values are calculated by cross-table analysis (c2 test). ACC, Adenocarcinoma; LCC, large-cell carcinoma; SCC, squamous cell carci-
noma; UICC, Union for International Cancer Control; WHO, World Health Organization.
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NSCLC patients as adversely affecting survival.
Our series demonstrates a better outcome for pT1-pT4
N0 M0 patients without lymphatic and vascular invasion.
The authors of 2 previously published large studies
(n ¼ 746 and n ¼ 995) did not differ between lymphatic
and vascular invasion. Ruffini and colleagues16 showed
the negative effect of microscopic vascular invasion in
pT1-T2 N0 NSCLC patients. Microscopic vessel invasion,
found in 34% of all cases, was associated with poorer pa-
tient survival.16 Tsuchiya and colleagues17 suggested con-
sidering vessel invasion to the TNM staging system based
on their studies of 995 patients with stages I and II disease.
Regarding the data presented herein, only lymphatic, not
vascular, invasion significantly discriminated survival in the
early stages. Possibly, the missing significance for vascular
invasion results from low patient numbers in our study. Pe-
chet and colleagues18 could demonstrate a drastically re-
duced survival in patients with positive vascular invasion
in early NSCLC. Generally, separate analysis of both fac-
tors should be performed. In a recently published meta-
study by Wang and colleagues,19 considering a total of784 The Journal of Thoracic and Cardiovascular Surg16,535 patients from 52 studies, blood vessel invasion
occurred in a total of 29.8% and negatively affected overall
survival in the overall patient cohort and especially in stage
IA patients. In addition, the presence of both lymphatic and
vascular invasion increased with increasing tumor stages in
our study group. Thismight reflect a combination of a higher
stochastical chance to invade vessels in larger tumors, and
the increasing malignant potential of the tumor cells. As
in higher stages, at least in our study population, the effect
of vessel invasion did not influence survival anymore. It
seems that vessel invasion is a distractor of malignant
potential, especially in early NSCLC.
These findings support the hypothesis that the group of
stage IA NSCLC patients is heterogeneous regarding their
tumor risk profile, and a subgroup of these patients might
benefit from adjuvant therapy. Tsuchiya and colleagues20
compared the survival rates of stage IA patients (staged
by the fifth TNM classification system) receiving uracil-
tegafur therapy with and without vascular invasion. In their
series, patients with vascular invasion had an improved sur-
vival with adjuvant therapy.20 Although large pooled meta-
analyses failed to demonstrate a clear benefit of adjuvantery c October 2013
FIGURE 3. Estimated overall survival according to lymphatic invasion (P¼ .000) (A), vascular invasion (P¼ .008) (B), lymphatic invasion for Union for
International Cancer Control (UICC) stage IA tumors (P<.000) (C), and lymphatic invasion for UICC stage IB tumors (P ¼ .028) (D) (log-rank test,
including 95% confidence intervals).
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TABLE 2. Univariable and multivariable Cox regression analyses
Univariable analysis HR 95% CI P value
L0 vs L1 3.069 1.931-4.877 .000
V0 vs V1 2.018 1.188-3.427 .009
UICC stage
IA Reference .000
IB 1.208 0.740-1.974 .450
IIA 2.723 1.449-5.117 .002
IIB 2.265 1.224-4.192 .009
IIIA 46.506 12.589-171.809 .000
Age groups, y
<60 Reference .077
60-70 1.090 0.640-1.855 .752
>70 1.669 1.012-2.753 .045
Histologic type
ACC Reference .665
SCC 0.827 0.534-1.280 .394
LCC 1.669 0.550-1.827 .993
WHO grade
I Reference .302
II 1.178 0.365-3.800 .784
III 1.629 0.501-5.302 .418
IV 2.730 0.647-11.510 .171
Male vs female sex 1.255 0.824-1.914 .290
Multivariable analysis HR 95% CI P value
L category
L0 Reference
L1 3.002 1.780-5.061 .000
UICC stage
IA Reference .000
IB 1.220 0.743-2.003 .432
IIA 3.063 1.611-5.822 .001
IIB 1.753 0.923-3.331 .086
IIIA 25.724 6.418-103.111 .000
Age groups, y
<60 Reference .011
60-70 1.038 0.588-1.833 .897
>70 1.928 1.147-3.243 .013
V category
V0 Reference
V1 1.029 0.508-2.087 .936
HR, Hazard ratio; CI, confidence interval; L, lymphatic; V, vascular; UICC, Union for
International Cancer Control; ACC, adenocarcinoma; SCC, squamous cell carci-
noma; LCC, large-cell carcinoma; WHO, World Health Organization.
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vascular invasion should be considered as a criterion in
therapy decision making.
The limitations of our study include its retrospective de-
sign, the relatively small patient population, and a mixture
of histological subtypes. On the other hand, the surgical reg-
imen and type of lymphadenectomy were radical in all pa-
tients included in this study. In addition, our data pinpoint
toward better risk stratification in early tumor stages. These
patients have also not been subject to adjuvant therapy in
the past; hence, the potential bias of different adjuvant reg-
imens does not apply to this subgroup.786 The Journal of Thoracic and Cardiovascular SurgA larger sample size, with more vascular invasions,
would have resulted in clarifying the role of vascular inva-
sion as well.
In conclusion, lymphatic invasion affects overall survival
in nonmetastatic completely resected NSCLC patients and
represents an independent prognostic factor. In early tumor
stages (pT1a and pT1b), it should be considered as a high
risk factor and its role in therapy planning and selecting
patients in need of adjuvant therapy should be further
evaluated. These are especially important because this in-
formation is already provided in the routine histopathologic
report and no additional assays or molecular profiling is
necessary.
We thank Mr Eik Vettorazzi (Department of Medical Biometry
and Epidemiology, University Medical Center Hamburg-Eppen-
dorf, Hamburg, Germany) for his help in statistical analysis.
References
1. Sobin LH, Gospodarowicz M, Wittekind C, eds. TNM Classification of Malig-
nant Tumours. 7th ed. Hoboken, NJ: Wiley-Blackwell; 2010.
2. Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P.
The International Association for the Study of Lung Cancer Staging Project:
prognostic factors and pathologic TNM stage in surgically managed non-small
cell lung cancer. J Thorac Oncol. 2009;4:792-801.
3. Dicken BJ, Graham K, Hamilton SM, Andrews S, Lai R, Listgarten J, et al. Lym-
phovascular invasion is associated with poor survival in gastric cancer: an appli-
cation of gene-expression and tissue array techniques.Ann Surg. 2006;243:64-73.
4. Ishii M, OtaM, Saito S, Kinugasa Y, Akamoto S, Ito I. Lymphatic vessel invasion
detected by monoclonal antibody D2-40 as a predictor of lymph node metastasis
in T1 colorectal cancer. Int J Colorectal Dis. 2009;24:1069-74.
5. Arnaout-Alkarain A, Kahn HJ, Narod SA, Sun PA, Marks AN. Significance of
lymph vessel invasion identified by the endothelial lymphatic marker D2-40 in
node negative breast cancer. Mod Pathol. 2007;20:183-91.
6. Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, et al.
Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary
guideline of the German Respiratory Society and the German Cancer Society.
Pneumologie. 2011;65:39-59.
7. Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at var-
ious levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg.
1978;76:832-9.
8. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;
144:646-74.
9. Heon S, Johnson BE. Adjuvant chemotherapy for surgically resected non-small
cell lung cancer. J Thorac Cardiovasc Surg. 2012;144:S39-42.
10. Brechot JM, Chevret S, Charpentier MC, Appere de Vecchi C, Capron F,
Prudent J, et al. Blood vessel and lymphatic vessel invasion in resected nonsmall
cell lung carcinoma: correlation with TNM stage and disease free and overall sur-
vival. Cancer. 1996;78:2111-8.
11. Shields TW. Prognostic significance of parenchymal lymphatic vessel and blood
vessel invasion in carcinoma of the lung. Surg Gynecol Obstet. 1983;157:185-90.
12. Goldstein NS, Mani A, Chmielewski G, Welsh R, Pursel S. Prognostic factors in
T1 NOMO adenocarcinomas and bronchioloalveolar carcinomas of the lung. Am
J Clin Pathol. 1999;112:391-402.
13. Hanagiri T, Takenaka M, Oka S, Shigematsu Y, Nagata Y, Shimokawa H, et al.
Prognostic significance of lymphovascular invasion for patients with stage I
non-small cell lung cancer. Eur Surg Res. 2011;47:211-7.
14. Funai K, Sugimura H, Morita T, Shundo Y, Shimizu K, Shiiya N. Lymphatic ves-
sel invasion is a significant prognostic indicator in stage IA lung adenocarcinoma.
Ann Surg Oncol. 2011;18:2968-72.
15. Gabor S, Renner H, Popper H, Anegg U, Sankin O, Matzi V, et al. Invasion of
blood vessels as significant prognostic factor in radically resected T1-3N0M0
non-small-cell lung cancer. Eur J Cardiothorac Surg. 2004;25:439-42.
16. Ruffini E, Asioli S, Filosso PL, Buffoni L, Bruna MC, Mossetti C, et al. Signif-
icance of the presence of microscopic vascular invasion after complete resection
of stage I-II pT1-T2N0 non-small cell lung cancer and its relation with T-sizeery c October 2013
Nentwich et al General Thoracic Surgerycategories: did the 2009 7th edition of the TNM staging system miss something?
J Thorac Oncol. 2011;6:319-26.
17. Tsuchiya T, Hashizume S, Akamine S, Muraoka M, Honda S, Tsuji K, et al. Up-
staging by vessel invasion improves the pathology staging system of non-small
cell lung cancer. Chest. 2007;132:170-7.
18. PechetTT,CarrSR,Collins JE,CohnHE,Farber JL.Arterial invasionpredicts early
mortality in stage I non-small cell lung cancer.Ann Thorac Surg. 2004;78:1748-53.
19. Wang J, Chen J, Chen X, Wang B, Li K, Bi J. Blood vessel invasion as a strong
independent prognostic indicator in non-small cell lung cancer: a systematic
review and meta-analysis. PLoS One. 2011;6:e28844.The Journal of Thoracic and Ca20. Tsuchiya T, Akamine S, Muraoka M, Kamohara R, Tsuji K, Urabe S, et al. Stage
IA non-small cell lung cancer: vessel invasion is a poor prognostic factor and
a new target of adjuvant chemotherapy. Lung Cancer. 2007;56:341-8.
21. Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, Le Chevalier T,
et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in op-
erable non-small-cell lung cancer: two meta-analyses of individual patient data.
Lancet. 2010;375:1267-77.
22. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ,
et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collab-
orative Group. J Clin Oncol. 2008;26:3552-9.rdiovascular Surgery c Volume 146, Number 4 787
G
T
S
